Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Mohamed A, Ayman A, Deniece J, Wang T, Kovach C, Siddiqui MT, et al. P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas. Front Oncol. 2015;5:70.

Gkrouzman E, Kirou KA, Seshan SV, Chevalier JM. Minimal Change Disease as a Secondary and Reversible Event of a Renal Transplant Case with Systemic Lupus Erythematosus. Case Rep Nephrol. 2015;2015:987212.

Rabadan R, Inghirami G. JAK-STAT in lymphoproliferative disorders. Oncoscience. 2015;2(9):737-8.

Pagan JK, Marzio A, Jones MJ, Saraf A, Jallepalli PV, Florens L, et al. Degradation of Cep68 and PCNT cleavage mediate Cep215 removal from the PCM to allow centriole separation, disengagement and licensing. Nat Cell Biol. 2015;17(1):31-43.

Labbé DP, Zadra G, Ebot EM, Mucci LA, Kantoff PW, Loda M, et al. Role of diet in prostate cancer: the epigenetic link. Oncogene. 2015;34(36):4683-91.

Ginter PS, Petrova K, Hoda SA. The grossly "rusty" tumor of breast: invasive ductal carcinoma with osteoclast-like giant cells. Int J Surg Pathol. 2015;23(1):32-3.

Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson S-, et al. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015;13(10):1431-40.

Kim D-, Hwang I, Muller FL, Paik J-. Functional regulation of FoxO1 in neural stem cell differentiation. Cell Death Differ. 2015;22(12):2034-45.

Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorn DC, et al. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer Res. 2015;75(9):1838-45.

Yigit N, Covey S, Barouk-Fox S, Turker T, Geyer JT, Orazi A. Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Hum Pathol. 2015;46(8):1217-25.